Navigation Links
Moderate use averts failure of type 2 diabetes drugs in animal model
Date:10/27/2008

Drugs widely used to treat type 2 diabetes may be more likely to keep working if they are used in moderation, researchers at Washington University School of Medicine in St. Louis have found in a study using an animal model.

The drugs, sulfonylureas, help type 2 diabetics make more insulin, improving control of blood sugar levels. But in most patients the effects of sulfonylureas are lost after several years of use, causing insulin secretion to shut down. This typically forces patients to switch to regular insulin injections.

"Why this happens isn't clear yet, but we've found what may be cause for hope," says senior author Colin G. Nichols, Ph.D., the Carl F. Cori Professor and professor of cell biology and physiology. "We've shown in a mouse model that whatever causes this shutdown doesn't kill the insulin-making beta cells of the pancreas or stop them from making insulin. Instead, it somehow stops them from secreting insulin."

When they stopped receiving the drug, beta cells began secreting insulin again hours later. Nichols and co-author Maria Sara Remedi, Ph.D., instructor of cell biology and physiology, report the findings in Public Library of Science Medicine.

"I find these experimental observations very exciting," says Alan Permutt, M.D., professor of medicine and of cell biology and physiology. "But I'm very cautious that patients understand that the relevance of this model to human diabetes and its treatment still needs to be tested."

If human beta cells also survive and can continue to produce insulin after long-term sulfonylurea exposure, it may be possible to rethink treatment strategies, Nichols suggests.

"Doctors now prescribe new long-acting sulfonylureas to establish a chronic presence of the drug in the bloodstream," he says. "But it may be beneficial to use the older drugs that go away more quickly, allowing the beta cells time to recover."

Another potential option would be a
'/>"/>

Contact: Michael Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Moderate prenatal exposure to alcohol and stress in monkeys can cause touch sensitivity
2. Moderate quantities of dirt make more rain
3. High blood pressure, low energy -- a recipe for heart failure
4. Certain diseases, birth defects may be linked to failure of protein recycling system
5. Genetic variant mimics effect of heart failure medications
6. Many African-Americans have a gene that prolongs life after heart failure
7. Jefferson receives $11.6M NIH grant to study novel mechanisms of heart failure
8. Oocyte-specific gene mutations cause premature ovarian failure
9. Vitamin D: New way to treat heart failure?
10. Failure to bridle inflammation spurs atherosclerosis
11. Failure of the 1st attempt at assisted reproduction justifies at least 1 additional cycle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... commonly cultivated cacao plant in the world is revealed ... Researchers have utilised high quality DNA sequences to demonstrate the ... can lead to higher yielding cocoa plants that still produce better ... cacao tree ( Theobroma cacao L. ), but ...
... Plymouth University, and the Universidad Federal da Bahia in ... diversity and density of coral colonies off the coast ... El Nio event of 1997-98, creating an opportunity for ... major environmental incident of this nature can have on ...
... ecology has centered on the role of microbes in ... print in the journal Applied and Environmental Microbiology ... Australia, and collaborators show how changes in the populations ... at ecosystem levels. "Ecological theories developed for ...
Cached Biology News:Genome hints at markers for higher-producing, better-tasting chocolate 2Catastrophic climatic events leave corals facing a decade-long fight for recovery 2
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
(Date:9/2/2015)... R.I. , Sept. 2, 2015  Neurotech ... been enrolled in the multicenter Phase 2 clinical ... the long-term treatment of recurrent subfoveal choroidal neovascularization ... NT-503 is a unique vascular endothelial growth factor ... ECT implant. "This landmark proof-of-concept study ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human viral ... quarter and year ended December 31, 2010. At December ... million. Business HighlightsIDX184 Update In ...
... CSL Behring announces a special ... in conjunction with Rare Disease Day 2011 , an ... impact on people,s lives. The Dialogue spanned two ... information and ideas for patients, caregivers and healthcare providers. ...
... of biomass to fuel requires several steps: chemical pretreatment ... acid, detoxification to remove the toxic chemicals required in ... to fuels. Virginia Tech researchers have discovered an enzyme ... infused liquid biomass (hydrolysate), meaning that the detoxification step ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5Enzyme cocktail could eliminate a step in biofuel process 2
More cell-permeant than acridine orange....
HistoScan HRP Kit Universal Goat Kit...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Biology Products: